Get the Stockscreener App
10.49
5.41%
-0.60
After Hours:
10.49
Neogenomics Inc stock is traded at $10.49, with a volume of 4.97M.
It is down -5.41% in the last 24 hours and up +27.31% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$11.09
Open:
$10.29
24h Volume:
4.97M
Relative Volume:
2.67
Market Cap:
$1.37B
Revenue:
$745.97M
Net Income/Loss:
$-99.21M
P/E Ratio:
-13.57
EPS:
-0.7729
Net Cash Flow:
$-5.09M
1W Performance:
-8.30%
1M Performance:
+27.31%
6M Performance:
-10.11%
1Y Performance:
+41.57%
1-Day Range:
$10.05
$11.04
1-Week Range:
$10.05
$11.82
52-Week Range:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
10.49 | 1.44B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
472.63 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
181.35 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
573.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
128.34 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
360.54 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
NeoGenomics launches $275M convertible notes offering due 2032 - MSN
NeoGenomics launches $275M convertible notes offering By Investing.com - Investing.com South Africa
NeoGenomics launches $275M convertible notes offering - Investing.com
NeoGenomics Reports Convertible Notes Offering - marketscreener.com
NeoGenomics launches $275M convertible notes offering due 2032 with $41.25M overallotment option - TradingView
NeoGenomics (NASDAQ: NEO) launches $275M 2032 convertible notes and buyback plan - Stock Titan
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes - Business Wire
Lynn Tetrault sells 5,307 NEO shares under 10b5-1 (NASDAQ: NEO) - Stock Titan
NEO News | NEOGENOMICS INC (NASDAQ:NEO) - ChartMill
Neogenomics (NEO) director sells 5,307 shares, retains sizable stake - Stock Titan
[144] NEOGENOMICS INC SEC Filing - Stock Titan
NeoGenomics (NEO) Q1 2025 Earnings Transcript - AOL.com
(NEO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
NeoGenomics (NEO) director gains RSU grants and stock options, exercises awards - Stock Titan
Felicia Williams (NASDAQ: NEO) gains shares via RSUs and options - Stock Titan
NeoGenomics (NEO) director boosts holdings through option and RSU awards - Stock Titan
NeoGenomics (NASDAQ: NEO) director exercises RSUs and gains new options - Stock Titan
NeoGenomics (NEO) director adds shares via RSU release and new options - Stock Titan
NeoGenomics (NEO) director exercises 23,077 RSUs and receives new option, RSU grants - Stock Titan
NeoGenomics (NEO) director adds 23,077 shares through RSU vesting - Stock Titan
NeoGenomics (NEO) director reports RSU release and new stock option grants - Stock Titan
NeoGenomics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 6, 2023 to Discuss Your RightsNEO - TMX Newsfile
NeoGenomics Inc (NEO) Stock Up 6.5% and Still Undervalued -- GF Score: 68/100 - GuruFocus
William Blair Maintains NeoGenomics(NEO.US) With Hold Rating - Moomoo
Is NeoGenomics (NEO) Using Its ASCO ctDNA Focus To Redefine Its Precision Oncology Edge? - Yahoo Finance
NeoGenomics Inc. (NEO) Edges Higher as Stock Hovers Near Support in a Consolidative PhaseForce Index - The Legal Advocate
NeoGenomics to Present New Research at ASCO Annual Meeting 2026 - Business Wire
NeoGenomics Inc. (NEO) Edges Higher as Diagnostic Sector Shows Renewed InterestBull Pennant - The Legal Advocate
(NEO) Risk Channels and Responsive Allocation - Stock Traders Daily
NeoGenomics Investor Alert - TMX Newsfile
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $11 to $25 - Moomoo
Shareholders approve NeoGenomics (NASDAQ: NEO) equity plan amendment and board slate - Stock Titan
NeoGenomics Earnings Call Highlights NGS-Driven Momentum - TipRanks
NeoGenomics stock (US64049M2098): Q1 update keeps focus on cancer testing demand - AD HOC NEWS
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know - Yahoo Finance
NEOGENOMICS (NEO) 13G/A: Greenhouse reports 9,215,903 shares (7.1%) - Stock Titan
NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval - MSN
Oncology diagnostics group NeoGenomics meets investors at May, June conferences - Stock Titan
NeoGenomics to Participate in Upcoming Investor Conferences - The Joplin Globe
(NEO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
This NeoGenomics Insider Reduced Their Stake By 15% - Moomoo
Millennium group reports 2.22M NEO shares (1.7%) — Joint filing (NEO) - Stock Titan
NeoGenomics (NEO) EVP adds shares via RSU vesting while covering taxes - Stock Titan
NeoGenomics (NEO) COO exercises RSUs, withholds shares for taxes and holds 164,032 shares - Stock Titan
TradingKey - TradingKey
Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO? - Sahm
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
NeoGenomics Inc. (NEO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NeoGenomics to Host Second Quarter 2015 Earnings Conference Call and Webcast Live on Thursday, July 23, 2015 - ACCESS Newswire
NEO PE Ratio & Valuation, Is NEO Overvalued - Intellectia AI
First Light, Mathew Arens report 10.8% stakes in Neogenomics (NEO) - Stock Titan
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neogenomics Inc Stock (NEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TETRAULT LYNN A. | Director |
Jun 09 '26 |
Sale |
11.29 |
5,307 |
59,916 |
91,422 |
0.56%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):